Literature DB >> 6208030

Biochemical studies of the renal radiopharmaceutical compound dimercaptosuccinate. IV. Interaction of 99mTc-DMS and 99Tc-DMS complexes with blood serum proteins.

N Vanlić-Razumenic, J Petrovic, D Gorkic.   

Abstract

As a crucial step towards understanding the mechanism of localisation of radiopharmaceuticals in specific target organs, the interaction of the radiopharmaceuticals 99mTc-DMS and 99Tc-DMS with blood serum proteins was studied. The interaction of 99mTc-DMS radiopharmaceutical was examined from two aspects: total protein binding as well as specificity of binding to certain classes of proteins. After in vitro labelling of human sera with 99mTc-DMS, the following values of bound radioactivity to total serum proteins were determined: 65% +/- 3.2% by gel-filtration chromatography; 72% +/- 4.6% by dialysis; while on the basis of precipitation by perchloric and trichloroacetic acid 72.7% +/- 6.8% and 71% +/- 2.3%, respectively. Distribution of 99mTc-DMS or 99Tc-DMS among serum proteins was analysed by agarose gel electrophoresis of the sera at pH 8.6 after in vivo and in vitro labelling of human sera with 99m-Tc-DMS, while the same analysis was performed with 99Tc-DMS complex after in vitro labelling of human and rat sera as well as after in vivo application to the rats. The results obtained demonstrate that carrier serum proteins investigated by agarose gel electrophoresis were in the migration zone of alpha 2-, alpha 1- and beta 1-globulins, whereas the radioactivity found in the serum albumin zone was negligible. Interaction of both Tc-DMS complexes with proteins was very similar, and this conclusion was in good correlation with our previously obtained results in investigations concerning the biochemical behaviour of these complexes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6208030     DOI: 10.1007/bf00252873

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  8 in total

1.  Plasma protein binding of 99mTc-pyrophosphate.

Authors:  G B Saha; C M Boyd
Journal:  Int J Nucl Med Biol       Date:  1978

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Catabolism and protein binding of Tc-99m pyridoxylideneglutamate.

Authors:  A L Jansholt; K A Krohn; R C Stadalnik; N M Matolo; G L DeNardo
Journal:  J Nucl Med       Date:  1978-09       Impact factor: 10.057

4.  Chemical and biological studies on 99mTc-DMS--I: Formation of complexes by four different methods.

Authors:  I Ikeda; O Inoue; K Kurata
Journal:  Int J Nucl Med Biol       Date:  1977-01

5.  Mechanism of localization of 99mTc-labeled pyrophosphate and tetracycline in infarcted myocardium.

Authors:  M K Dewanjee; P C Kahn
Journal:  J Nucl Med       Date:  1976-07       Impact factor: 10.057

6.  Preparation of technetium-99-DMS renal complex in solution and its chemical and biological characterization.

Authors:  N Vanlić-Razumenić; J Petrović
Journal:  Int J Appl Radiat Isot       Date:  1982-04

7.  Morphine binding to human plasma proteins.

Authors:  G D Olsen
Journal:  Clin Pharmacol Ther       Date:  1975-01       Impact factor: 6.875

8.  The plasma protein binding of HIDA.

Authors:  R W Nicholson; K J Herman; R A Shields; H J Testa
Journal:  Eur J Nucl Med       Date:  1980-08
  8 in total
  2 in total

1.  What does protein binding of radiopharmaceuticals mean exactly?

Authors:  O Jeghers; A Piepsz; H R Ham
Journal:  Eur J Nucl Med       Date:  1990

2.  A kinetic model for 99mTc-DMSA in the rat.

Authors:  D C Maneval; D Z D'Argenio; W Wolf
Journal:  Eur J Nucl Med       Date:  1990
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.